Pharmaceuticals
These 3 stocks are troubled but I’m not ready to give up
If you were to tell me that Club names Estee Lauder (EL) or Danaher (DHR) would ever miss their quarters not once but twice, I would have told you to go get your head examined. These are clockwork beat and raise companies, which is why it’s so hard to value them now. Johnson & Johnson […]
Read More
Eli Lilly to acquire Dice Therapeutics for $2.4 billion in autoimmune treatment push
David Ricks, CEO, Eli Lilly Scott Mlyn | CNBC Eli Lilly on Tuesday said it struck a $2.4 billion deal to acquire Dice Therapeutics in a bid to bulk up its treatment portfolio for immune-related diseases. Eli Lilly will pay $48 per share in cash to buy Dice, representing around a 40% premium to where […]
Read More
Pfizer, Moderna and Novavax gear up for fall Covid vaccine rollout with an important head start
A pharmacist prepares to administer COVID-19 vaccine booster shots during an event hosted by the Chicago Department of Public Health at the Southwest Senior Center on September 09, 2022 in Chicago, Illinois. Scott Olson | Getty Images The U.S. Food and Drug Administration’s Covid strain selection for the next round of shots puts Pfizer, Moderna […]
Read More
FDA recommends that updated Covid shots target omicron subvariant XBB.1.5 this fall
XBB.1.5 strain of Covid CFOTO | Future Publishing | Getty Images The U.S. Food and Drug Administration on Friday recommended that vaccine manufacturers make single-strain Covid shots for the fall that target omicron subvariant XBB.1.5, the dominant strain of the virus nationwide. “Based on the totality of the evidence, FDA has advised manufacturers who will […]
Read More
FDA advisors raise doubts about seasonal updates to Covid vaccines as with flu shots
A person receives a COVID-19 vaccination dose, during a free distribution of COVID-19 rapid test kits for those who received vaccination shots or booster shots, at Union Station on January 7, 2022 in Los Angeles, California. Mario Tama | Getty Images The U.S. Food and Drug Administration’s independent panel of advisors raised doubts about the […]
Read More
FDA advisors recommend that new Covid vaccines target an omicron XBB variant this fall
A woman receives a booster dose of the Moderna coronavirus disease (COVID-19) vaccine at a vaccination centre in Antwerp, Belgium, February 1, 2022. Johanna Geron | Reuters The U.S. Food and Drug Administration’s independent panel of advisors on Thursday recommended that updated Covid shots for the fall and winter target one of the XBB variants, […]
Read More
Health insurance stocks slide after UnitedHealth warns more surgeries will drive up medical costs
Health insurer stocks dropped on Wednesday after UnitedHealth Group warned of higher medical costs as older Americans start to catch up on surgeries they delayed during the Covid pandemic. Shares of UnitedHealth, the largest U.S. healthcare provider by market value, closed around 6% lower. Medicare-focused insurer Humana declined 11%. Elevance Health closed roughly 7% lower, […]
Read More
Covid vaccine maker Novavax sees a pathway to survival – but it won’t be easy
Medical syringes and Novavax logo displayed in the background are seen in this illustration photo taken in Krakow, Poland on December 2, 2021. Jakub Porzycki | NurPhoto | Getty Images Novavax has a clear message for Wall Street: The cash-strapped Covid vaccine maker sees a pathway to survival. Maryland-based Novavax said as much last month […]
Read More
Eli Lilly CEO says Medicare price negotiations could harm drug development
David Ricks, CEO, Eli Lilly. Scott Mlyn | CNBC Eli Lilly CEO David Ricks on Tuesday said Medicare price negotiations, which aim to cut costs for older Americans, could potentially harm drug development. “I’m really worried about the harm this will do to new cures and possibilities in medicine,” Ricks said in an interview on […]
Read More
Illumina acquisition of Grail wins support from GOP lawmakers, state AGs as FTC tries to block
Rafael Henrique | Lightrocket | Getty Images Republican lawmakers, state attorneys general and several advocacy groups have voiced their support for Illumina’s acquisition of cancer test developer Grail while the Federal Trade Commission fights to unwind the deal. The groups filed 14 amicus briefs Monday urging the U.S. 5th Circuit Court of Appeals to reverse […]
Read More